Katrina J. Church - Mar 14, 2022 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
SVP & Chief Compliance Officer
Signature
/s/Anthony D'Adamio, Attorney-in-Fact
Stock symbol
BVS
Transactions as of
Mar 14, 2022
Transactions value $
-$1,850
Form type
4
Date filed
3/16/2023, 09:17 PM
Next filing
Jun 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise +3.46K +138.24% 5.96K Mar 14, 2023 Direct F1
transaction BVS Class A Common Stock Sale -$1.85K -1.33K -22.36% $1.39 4.62K Mar 15, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Award $0 +13.8K $0.00 13.8K Mar 14, 2022 Class A Common Stock 13.8K Direct F1, F4
transaction BVS Restricted Stock Units Options Exercise $0 -3.46K -25% $0.00 10.4K Mar 14, 2022 Class A Common Stock 3.46K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 Reflects shares sold to cover taxes upon the vesting of the RSUs on March 14, 2023 pursuant to a standing 10b5-1 instruction.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.3692 to $1.423, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The original grant of 13,823 RSUs vest in four approximately equal annual installments beginning on March 14, 2023.